Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III...
May 31, 2026 01:15 ET | Source: Novartis Pharma AG

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent...
May 26, 2026 01:15 ET | Source: Novartis Pharma AG

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be...
May 21, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report...
May 17, 2026 15:30 ET | Source: Novartis Pharma AG

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...
May 07, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the...
May 07, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 28, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority...